Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks
ML Heacock, DF Stefanick, JK Horton, SH Wilson - DNA repair, 2010 - Elsevier
The combination of poly (ADP-ribose) polymerase (PARP) inhibitors and alkylating agents is
currently being investigated in cancer therapy clinical trials. However, the DNA lesions
producing the synergistic cell killing effect in tumors are not fully understood. Treatment of
human and mouse fibroblasts with the monofunctional DNA methylating agent methyl
methanesulfonate (MMS) in the presence of a PARP inhibitor has been shown to trigger a
cell cycle checkpoint response. Among other changes, this DNA damage response to …
currently being investigated in cancer therapy clinical trials. However, the DNA lesions
producing the synergistic cell killing effect in tumors are not fully understood. Treatment of
human and mouse fibroblasts with the monofunctional DNA methylating agent methyl
methanesulfonate (MMS) in the presence of a PARP inhibitor has been shown to trigger a
cell cycle checkpoint response. Among other changes, this DNA damage response to …